Brief: Puretech Health Announces Positive Topline Data From Phase 1b Trial Of Lyt-200
22/04/2026 12:45
April 22 (Reuters) - PureTech Health PLC PRTC.L: PURETECH REPORTS POSITIVE TOPLINE DATA FROM PHASE 1B TRIAL OF LYT-200 IN RELAPSED/REFRACTORY (R/R) HIGH-RISK (HR) MYELODYSPLASTIC SYNDROME (MDS) AND R/R ACUTE MYELOID LEUKEMIA (AML) PURETECH HEALTH - LYT-200 SHOWS FAVORABLE SAFETY PROFILE WITH NO SERIOUS ADVERSE EVENTS IN PHASE 1B Source text: ID:nBw73PMvBa Further company coverage: PRTC.L ((Reuters.Briefs@thomsonreuters.com))